επ.Καθ.Jacques Medioni
Παθολόγος Ογκολόγος.
Business address
Medical Oncology Service
Georges Pompidou European Hospital
20, rue Leblanc
75015 Paris
Tél : 33 1 56 09 27 81. Fax : 33 1 56 09 54 81
[email protected]
HOSPITAL AND UNIVERSITY FUNCTIONS Assistant Professor – Hospital Practitioner, 2010.
Areas of expertise: breast, gynaecological & urological cancers
Head of Phase 1 Clinical Trials Unit
Medical Director (Praticien Hospitalier Universitaire) (2006-2010)
Senior Registrar (Chef de Clinique Assistant) (2002-2006).
Intership (1995-2000). UNIVERSITY DEGREES Proficiency in Clinical Pharmacology (2011).
PhD in Sciences (2007).
Proficiency in Medical Oncology (2002).
Qualification as a Specialist in Public Health and Social Medicine (2000).
Master of Sciences (1999).
Medical Doctorate (1997). PROFESSIONAL ONCOLOGY SOCIETIES. REGULATORY AGENCIES American Society of Clinical Oncology
European Society for Medical Oncology
American Association for Cancer Research.
Expert Agence Nationale de Sécurité du Médicament (french FDA) CLINICAL TRIAL
Ten clinical trials as principal investigator.
Dozens of clinical trials as co-investigator.
Total number of articles in English published in a journal with peer review committee: 50 (total index cotation: 146,331).
First author: 8 articles
Second author: 10 articles
Last author: 2 articles
Total number of articles in French published in a journal with peer review committee with peer review committee: 10 (total index cotation: 4, 196).
Five publications
Mardjuadi F, Medioni J, Kerger J, D’Hondt L, Canon JL, Duck L, Musuamba F, Oudard S, Clausse M, Moxhon A, Machiels JP. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naive patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2012 Aug;70(2):293-303. (IF : 2,883).
Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Schöffski P, Barrascout E, Morel A, Escudier B, Lang H, Zucman-Rossi J, Medioni J. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol. 2010 Oct 11. (IF : 5,179)
Medioni J, Banu E, Helley D, Scotte F, Fournier L, Mejean A, Chedid A, Azizi M, Andrieu JM, Oudard S. Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone metastatic renal cell carcinoma: a case series. Eur Urol. 2009 Jan 13. (IF : 5,634)
Frangié C, Lefaucheur C, Medioni J, Jacquot C, Hill G, Nochy D. Renal thrombotic microangiopathy during treatment by anti-VEGF for a metastatic renal carcinoma. Lancet Oncol. 2007 Feb;8(2):177-8. (IF : 10,12)
Leuraud P, Taillandier L, Medioni J, Aguirre-Cruz L, Criniere E, Marie Y, Kujas M, Golmard JL, Duprez A, Delattre JY, Sanson M, Poupon MF. Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Cancer Res. 2004 Jul 1;64(13):4648-53. (IF : 8,649)